ACM
BLTE

ADAR1 Capital Management’s Belite Bio BLTE Stock Holding History

ADAR1 Capital Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,880
Closed -$4.29M – 289
2026
Q1 		$4.29M Sell
26,880
-12,959
-33% -$2.18M 0.25% 84
2025
Q4 		$6.37M Buy
+39,839
New +$4.72M 0.47% 45

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ADAR1 Capital Management's BLTE Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 26,880 shares — an estimated $4.29M sold.

ADAR1 Capital Management first reported a position in BLTE in Q4 2025 and held it in 2 quarters. The position peaked at $6.37M in Q4 2025. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 26,880 Belite Bio shares in Q2 2026, an estimated $4.29M.
  • ADAR1 Capital Management first reported a position in Belite Bio in Q4 2025 and held it in 2 quarters.
  • ADAR1 Capital Management's Belite Bio position peaked at $6.37M in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.